These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30479089)

  • 21. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer.
    Nakao S; Minaguchi T; Itagaki H; Hosokawa Y; Shikama A; Tasaka N; Akiyama A; Ochi H; Matsumoto K; Satoh T
    J Ovarian Res; 2020 May; 13(1):55. PubMed ID: 32375852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis.
    Chen P; Zhang CY
    Front Oncol; 2022; 12():732322. PubMed ID: 35433452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies.
    Gu D; Szallasi A
    Anticancer Res; 2017 Sep; 37(9):4717-4726. PubMed ID: 28870890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    Xu K; Yang S; Zhao Y
    Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
    Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
    J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis.
    Taliento C; Morciano G; Nero C; Froyman W; Vizzielli G; Pavone M; Salvioli S; Tormen M; Fiorica F; Scutiero G; Scambia G; Giorgi C; Greco P; Pinton P
    Int J Gynecol Cancer; 2024 Jun; 34(6):906-918. PubMed ID: 38658022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
    Yu L; Deng L; Li J; Zhang Y; Hu L
    Gynecol Oncol; 2013 Feb; 128(2):391-6. PubMed ID: 23142075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis.
    Zhang W; Zhang Z; Qian L
    World J Surg Oncol; 2024 Jan; 22(1):8. PubMed ID: 38172843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis.
    Wang K; Guan C; Yu J; Jin X; Sun L; Zheng L; Xia L; Zhang Y
    Oncotarget; 2017 Sep; 8(43):75528-75543. PubMed ID: 29088888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association of pretreatment thrombocytosis with prognosis and clinicopathological significance in cervical cancer: a systematic review and meta-analysis.
    Cheng J; Zeng Z; Ye Q; Zhang Y; Yan R; Liang C; Wang J; Li M; Yi M
    Oncotarget; 2017 Apr; 8(15):24327-24336. PubMed ID: 28212582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Huang C; Lin X; He J; Liu N
    Gynecol Oncol; 2021 May; 161(2):613-620. PubMed ID: 33674144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
    Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
    PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis.
    Wang Q; Feng X; Liu X; Zhu S
    Front Oncol; 2022; 12():868061. PubMed ID: 35463345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological and prognostic significance of thyroid transcription factor-1 expression in small cell lung cancer: A systemic review and meta-analysis.
    Wang Y; Wu Y; Li J; Li J; Che G
    Pathol Res Pract; 2019 Dec; 215(12):152706. PubMed ID: 31704153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role systematic lymphadenectomy plays in determining the survival outcome for advanced ovarian cancer patients: a meta-analysis.
    Xu D; Xue J; Rozan R; Li L
    Ann Palliat Med; 2020 May; 9(3):912-920. PubMed ID: 32389005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.
    Nie D; Yang E; Li Z
    BMC Cancer; 2019 Jan; 19(1):73. PubMed ID: 30646853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
    Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.